What Happened?

On december 11, 2023, ⁤the Ministry of Food and Drug Safety (MFDS) ​in South Korea⁣ approved the⁢ expanded use of koselugo (selumetinib) to treat adults with neurofibromatosis type 1 (NF1)⁣ who have symptomatic and inoperable plexiform neurofibromas. AstraZeneca Korea⁤ announced the​ approval on⁤ December 15, 2023.

Koselugo is now the onyl treatment⁤ in Korea approved for both children (aged 3 years and ​older) and adults⁤ with this specific NF1 manifestation. Prior to this expansion, treatment options for adult NF1​ patients in korea were severely limited.

Understanding Neurofibromatosis Type 1 (NF1)

Neurofibromatosis ‌type ​1 (NF1) is a rare genetic disorder ​caused by a mutation in the NF1 gene. This gene provides instructions for making a protein called neurofibromin, which helps regulate cell growth. A malfunctioning neurofibromin protein can lead to the uncontrolled‍ growth of tumors along nerves throughout the body.

Key characteristics of ​NF1 include:

• Café-au-lait spots: Flat, light brown spots on the ⁤skin.
• Axillary and inguinal ⁢freckling: Freckles in the armpits and groin.
• Plexiform‌ neurofibromas: Tumors that grow along nerves,often causing pain,disfigurement,and functional‌ impairment.
• Other symptoms: Learning disabilities, skeletal abnormalities, and increased risk of certain‌ cancers.

Plexiform neurofibromas develop in 30-50% of individuals with NF1. The ‌Children’s Tumor Foundation provides extensive information about NF1.

Koselugo: How it Works

Koselugo (selumetinib) is a ‍MEK inhibitor.MEK (mitogen-activated protein kinase kinase) is a protein involved in cell signaling pathways that control cell growth and proliferation. By ⁤inhibiting ​MEK, Koselugo helps⁤ to slow or stop the growth of plexiform neurofibromas.

The drug was initially approved⁤ for pediatric patients with NF1⁣ and inoperable plexiform neurofibromas. This recent approval expands its use to adults, addressing a notable ‍unmet medical need.

Impact on Korean Patients

Kim⁢ Cheol-woong, Executive Director of astrazeneca Korea’s Rare Disease Division, emphasized ⁤the ‌importance of this approval. He stated​ that NF1 symptoms frequently enough persist or worsen throughout life,‌ requiring ongoing treatment,​ and that adult patients in Korea previously had very few options. ‍ ‍AstraZeneca Korea is committed to increasing treatment accessibility and improving the quality of life ‌for NF1 patients.

This approval represents a significant​ step forward for NF1 patients in Korea, ⁤offering a new⁢ hope for ⁢managing their condition and improving their long-term outcomes.